{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:04:03Z","timestamp":1784603043953,"version":"3.55.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":103,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.msard.2023.104500","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T11:59:05Z","timestamp":1672747145000},"page":"104500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam\u00ae (monomethyl fumarate) versus Vumerity\u00ae (diroximel fumarate)"],"prefix":"10.1016","volume":"70","author":[{"given":"Franck S.","family":"Rousseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurene","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany N.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Lategan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina R","family":"Berkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104500_bib0003","series-title":"Tecfidera\u00ae (Dimethyl Fumarate) Prescribing Information and Patient Information","year":"2020"},{"key":"10.1016\/j.msard.2023.104500_bib0006","unstructured":"Biogen. Vumerity\u00ae (diroximel fumarate) prescribing information and patient information, 2021. DailyMed - VUMERITY- diroximel fumarate capsule (nih.gov). Accessed 16 December 2021."},{"key":"10.1016\/j.msard.2023.104500_bib0007","unstructured":"CDER US FDA. Clinical pharmacology and biopharmaceutics review(s). Application Number 211855Orig1s000. Rev_211855(2)_package_Redacted.pdf (fda.gov). Accessed 16 December 2021."},{"key":"10.1016\/j.msard.2023.104500_bib0008","unstructured":"Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for Industry: bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations (Draft March 2014). Available at: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM389370.pdf. Accessed on 9 July 2020."},{"issue":"12","key":"10.1016\/j.msard.2023.104500_bib0002","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2023.104500_bib0001","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2023.104500_bib0005","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-021-00799-9","article-title":"Pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam\u2122 (monomethyl fumarate) or Tecfidera \u00ae (dimethyl fumarate)","volume":"35","author":"Lategan","year":"2021","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.msard.2023.104500_bib0004","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1007\/s12325-019-01085-3","article-title":"Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study","volume":"36","author":"Palte","year":"2019","journal-title":"Adv. Ther."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:17Z","timestamp":1761901457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":8,"alternative-id":["S2211034823000044"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104500","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam\u00ae (monomethyl fumarate) versus Vumerity\u00ae (diroximel fumarate)","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Banner Life Sciences LLC. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104500"}}